V
Volastra Therapeutics
Developing novel therapies for patients with metastatic cancers
About Volastra Therapeutics
Volastra Therapeutics is a clinical-stage biopharmaceutical startup that operates in the healthcare sector, specifically in the field of cancer research and treatment. The company's primary focus is on the discovery and development of cancer drugs that target chromosomal instability (CIN), a characteristic found in 60-80% of all tumors and often associated with aggressive disease and poor survival rates.
Read full description
Volastra's business model revolves around the development of innovative treatments and their subsequent commercialization. The company's main clients are patients suffering from cancer, particularly those with aggressive forms of the disease. The company generates revenue through the sale of its developed drugs and treatments.
Currently, Volastra has two lead clinical programs in progress, both of which target KIF18A, a protein that plays a crucial role in the division of cancer cells. The company recently announced the dosing of the first patient in a Phase I/II clinical trial evaluating one of their novel KIF18A inhibitors, VLS-1488.
In addition to its clinical trials, Volastra is also actively involved in research and development. The company recently presented preclinical data on two of its novel KIF18A inhibitors at the AACR 2023 conference. This indicates that the company is not only focused on the commercialization of its existing treatments but is also dedicated to the discovery of new, potentially more effective cancer treatments.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- New York City, United States
- Employees
- 42
- Open positions
- 2
- Dealroom signal
- 64.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Volastra Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | May 2024 | $15M | $60M | Undisclosed | ↗ |
| SERIES AOther financing | Mar 2023 | $60M | $240M | Meyer Ventures · Vida Ventures · Eli Lilly · Catalio Capital Management | ↗ |
Growth signals
Latest recorded traffic for Volastra Therapeutics is 3.7K monthly website visits, up 60.9% over the last three months. Volastra Therapeutics's team declined 2.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
Polaris Partners
GF Securities
Droia Oncology Ventures
Quark Venture
ARCH Venture Partners
Vida Ventures
Catalio Capital Management
Series A3 investors entered at this stage
- MVMeyer Ventures
Eli Lilly
Cornell University
Other known investors1 additional known investor
Cornell Tech
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Volastra Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Volastra Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.